Aβ misfolding in blood plasma is inversely associated with body mass index even in middle adulthood.
Alzheimer’s disease
Amyloid beta misfolding
BMI
cohort study
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
30 08 2021
30 08 2021
Historique:
received:
17
02
2021
accepted:
13
08
2021
entrez:
31
8
2021
pubmed:
1
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
To understand the potential for early intervention and prevention measures in Alzheimer's disease, the association between risk factors and early pathological change needs to be assessed. Hence, the aim of this study was to determine whether risk factors of Alzheimer's clinical syndrome (clinical AD), such as body mass index (BMI), are associated with Aβ misfolding in blood, a strong risk marker for AD among older adults. Information on risk factors and blood samples were collected at baseline in the ESTHER study, a population-based cohort study of older adults (age 50-75 years) in Germany. Aβ misfolding in blood plasma was analyzed using an immuno-infrared-sensor in a total of 872 participants in a nested case-control design among incident dementia cases and matched controls. Associations between risk factors and Aβ misfolding were assessed by multiple logistic regression. For comparison, the association between the risk factors and AD incidence during 17 years of follow-up was investigated in parallel among 5987 cohort participants. An inverse association with Aβ misfolding was seen for BMI at age 50 based on reported weight history (aOR 0.64, 95% CI 0.43-0.96, p = 0.03). Similar but not statistically significant associations were seen for BMI at baseline (i.e., mean age 68) and at age 40. No statistically significant associations with Aβ misfolding were found for other risk factors, such as diabetes, smoking, and physical activity. On the other hand, low physical activity was associated with a significantly reduced risk of developing clinical AD compared to physical inactivity. Our results support that AD pathology may be detectable and associated with reduced weight even in middle adulthood, many years before clinical diagnosis of AD. Physical activity might reduce the risk of onset of AD symptoms.
Sections du résumé
BACKGROUND
To understand the potential for early intervention and prevention measures in Alzheimer's disease, the association between risk factors and early pathological change needs to be assessed. Hence, the aim of this study was to determine whether risk factors of Alzheimer's clinical syndrome (clinical AD), such as body mass index (BMI), are associated with Aβ misfolding in blood, a strong risk marker for AD among older adults.
METHODS
Information on risk factors and blood samples were collected at baseline in the ESTHER study, a population-based cohort study of older adults (age 50-75 years) in Germany. Aβ misfolding in blood plasma was analyzed using an immuno-infrared-sensor in a total of 872 participants in a nested case-control design among incident dementia cases and matched controls. Associations between risk factors and Aβ misfolding were assessed by multiple logistic regression. For comparison, the association between the risk factors and AD incidence during 17 years of follow-up was investigated in parallel among 5987 cohort participants.
RESULTS
An inverse association with Aβ misfolding was seen for BMI at age 50 based on reported weight history (aOR 0.64, 95% CI 0.43-0.96, p = 0.03). Similar but not statistically significant associations were seen for BMI at baseline (i.e., mean age 68) and at age 40. No statistically significant associations with Aβ misfolding were found for other risk factors, such as diabetes, smoking, and physical activity. On the other hand, low physical activity was associated with a significantly reduced risk of developing clinical AD compared to physical inactivity.
CONCLUSIONS
Our results support that AD pathology may be detectable and associated with reduced weight even in middle adulthood, many years before clinical diagnosis of AD. Physical activity might reduce the risk of onset of AD symptoms.
Identifiants
pubmed: 34461995
doi: 10.1186/s13195-021-00889-2
pii: 10.1186/s13195-021-00889-2
pmc: PMC8406782
doi:
Substances chimiques
Amyloid beta-Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Informations de copyright
© 2021. The Author(s).
Références
Mol Psychiatry. 2016 Jul;21(7):910-5
pubmed: 26324099
Alzheimers Res Ther. 2020 Dec 24;12(1):169
pubmed: 33357241
Cell Mol Life Sci. 2011 Apr;68(8):1429-38
pubmed: 20853129
JAMA. 2004 Nov 10;292(18):2237-42
pubmed: 15536110
Ann Intern Med. 2006 Jan 17;144(2):73-81
pubmed: 16418406
J Neurosci. 2014 Jul 2;34(27):9096-106
pubmed: 24990930
J Alzheimers Dis. 2014;38(1):201-9
pubmed: 23948937
Exp Gerontol. 2020 Apr;132:110838
pubmed: 31981682
JAMA. 2017 Apr 11;317(14):1443-1450
pubmed: 28399252
Oncotarget. 2017 Oct 31;8(62):104706-104716
pubmed: 29285207
Clin Interv Aging. 2014 Apr 12;9:661-82
pubmed: 24748784
Eur J Epidemiol. 2014 Mar;29(3):171-9
pubmed: 24671603
BMC Geriatr. 2019 Jul 2;19(1):181
pubmed: 31266451
Arch Neurol. 2005 Jan;62(1):55-60
pubmed: 15642850
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
EMBO Mol Med. 2018 May;10(5):
pubmed: 29626112
Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12
pubmed: 17245412
Mol Neurobiol. 2012 Apr;45(2):366-78
pubmed: 22415442
Neurobiol Aging. 2020 Sep;93:124-130
pubmed: 32249013
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Anal Chem. 2016 Mar 1;88(5):2755-62
pubmed: 26828829
Oncotarget. 2018 Oct 5;9(78):34691-34698
pubmed: 30410669
Mol Psychiatry. 2020 May 13;:
pubmed: 32404947
Dtsch Med Wochenschr. 2004 Dec 3;129(49):2643-7
pubmed: 15578318
Alzheimers Dement. 2018 May;14(5):601-609
pubmed: 29169013
Alzheimers Dement (Amst). 2021 Feb 10;13(1):e12151
pubmed: 33614887
Alzheimers Dement (Amst). 2019 Mar 12;11:257-263
pubmed: 30911600
Neurology. 2011 Nov 22;77(21):1913-20
pubmed: 22105948
J Alzheimers Dis. 2016 Jun 18;53(3):1097-105
pubmed: 27340843
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Alzheimers Dement. 2020 Feb;16(2):283-291
pubmed: 31611055
JAMA Neurol. 2017 Jun 1;74(6):718-726
pubmed: 28418521
J Alzheimers Dis. 2019;69(3):817-827
pubmed: 31156169
J Am Med Dir Assoc. 2016 Oct 1;17(10):881-8
pubmed: 27324809